OREANDA-NEWS. June 16, 2015. Michelson Diagnostics, a medical device company focused on multi-beam Optical Coherence Tomography ('OCT') technology, today announces that data showing significant improvement in the diagnosis of basal-cell carcinoma (BCC) using its VivoSight multibeam OCT scanner will be presented at the World Congress of Dermatology (Vancouver, June 8-13).  In addition to being an efficient, non-invasive way to diagnose BCC and other non-melanoma skin cancers, using the VivoSight OCT scanner has the potential to reduce biopsies and surgery, thereby reducing scarring for patients.

Joint lead investigator, Dr Martina Ulrich, CMB Collegium, Berlin, Germany, will outline the results of this independent multi-centre, prospective clinical study into the use of VivoSight and discuss their implications for the diagnosis and management of BCC.

"Based on this pivotal research, we believe that VivoSight scans should become the gold standard for non-invasive diagnosis and monitoring of non-melanoma skin cancer," stated Andy Hill, Chief Executive Officer of Michelson Diagnostics. "We are now expanding the availability of our new generation VivoSight scanner in Germany and select territories in Europe."

Data from the study were first published online in the British Journal of Dermatology in April. The BJD paper can be viewed and downloaded from: http://onlinelibrary.wiley.com/doi/10.1111/bjd.13853/abstract.

VivoSight has CE/TGA regulatory-clearance and FDA 510(k) clearance in the United States and is available for sale in Europe, USA and Australia.